

## Scholar Rock to Present at Cowen & Company 36th Annual Health Care Conference

March 1, 2016

*CAMBRIDGE*, *Mass., March 1, 2016* – Scholar Rock, a biotechnology company focused on discovering and developing drugs that selectively target supracellular activation of growth factors in the disease microenvironment, today announced that Nagesh Mahanthappa, PhD, President and Chief Executive Officer of Scholar Rock, will present a company overview at the Cowen & Company 36<sup>th</sup> Annual Health Care Conference on Tuesday, March 8, 2016, at 9:30 a.m. EST in Boston, MA.

## About Scholar Rock

Scholar Rock is a biotechnology company focused on discovering and developing a novel class of biologic therapies that target supracellular activation of growth factors in the disease microenvironment. The Company's initial proprietary and partnered drug discovery programs target specific growth factors which are present in the microenvironments of significant diseases, including fibrosis, musculoskeletal diseases, immuno-oncology and autoimmune diseases. Scholar Rock was founded upon discoveries made by its scientific founders, Professors Timothy Springer, PhD, and Leonard Zon, MD, of Boston Children's Hospital and Harvard Medical School, related to the molecular mechanisms of supracellular activation. The company is backed by leading investors, including Polaris Partners, Timothy Springer, ARCH Venture Partners, Fidelity Investments, EcoR1 Capital, The Kraft Group, and Cormorant Asset Management.

Investor Contact: Stephanie Ascher Stern Investor Relations, Inc. Tel: 212-362-1200 stephanie@sternir.com

Media Contact: Kathryn Morris The Yates Network Tel: 845-635-9828 kathryn@theyatesnetwork.com